Exhibit 99.1  Gemini Therapeutics Provides Corporate Update

Remote-First-Company/Mass. - February** **28, 2022** - Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring.

This is the opening of the release as filed. Read the full document on SEC.gov, or read it in full on SPAC Watch with the trust, deadline and warrant terms alongside it.